The First Therapy Approved in 20 Years to Slow Progression of CKD

Learn about the landmark results of the DAPA-CKD trial and the new indication of FORXIGA® (dapagliflozin) to reduce the risk of progressive decline in kidney function in adults with proteinuric chronic kidney disease (CKD Stage 2,3 or 4 and urine ACR ≥ 30 mg/g).

Click here for more information and to register.